EyePoint Pharmaceuticals (NASDAQ: EYPT) has granted non-statutory stock options to two new employees as inducement awards outside its 2023 Long-Term Incentive Plan. The grants, approved by the Compensation Committee, comply with NASDAQ Listing Rule 5635(c)(4). Key details include:
- 43,000 shares of common stock options granted
- Grant date: September 13, 2024
- Exercise price: $9.10 per share (closing price on grant date)
- Ten-year term
- Vesting over four years: 25% after one year, remainder in monthly installments over three years
- Vesting contingent on continued employment
These inducement awards aim to attract and retain talent in EyePoint’s mission to develop therapeutics for serious retinal diseases.
EyePoint Pharmaceuticals (NASDAQ: EYPT) ha concesso opzioni su azioni non statutarie a due nuovi dipendenti come premi di induzione al di fuori del suo Piano di Incentivi a…
